進行性滑膜肉腫または粘液様/円形細胞脂肪肉腫の被験者を対象とした Spearhead 1 研究
進行性滑膜肉腫または粘液様/円形細胞脂肪肉腫の被験者におけるADP-A2M4 SPEAR™ T細胞の第2相単群非盲検臨床試験
This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- City of Hope
-
Palo Alto、California、アメリカ、94305
- Stanford Cancer Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado
-
-
Florida
-
Jacksonville、Florida、アメリカ、33612
- Mayo Clinic Jacksonville
-
Tampa、Florida、アメリカ、33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University Robert H. Lurie Comprehensive Cancer Center
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- National Cancer Institute
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
Boston、Massachusetts、アメリカ、02215
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
-
New York
-
New York、New York、アメリカ、10065
- Memorial Sloan-Kettering Cancer Center
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- Ohio State University
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37212
- Vanderbilt
-
-
Texas
-
Houston、Texas、アメリカ、77030
- MD Anderson Cancer Center
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Fred Hutch
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of WI Froedtert Hospital
-
-
-
-
-
London、イギリス、NW1 2PG
- UCLH Cancer Clinical Trials Unit
-
Manchester、イギリス、M20 4BX
- The Christie NHS Foundation Trust
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- Princess Margaret Cancer Centre
-
-
-
-
-
Madrid、スペイン、28040
- Start Madrid-FJD, Fundación Jimѐnez Díaz
-
Seville、スペイン、41013
- Hospital Universitario Virgen del Rocio
-
-
Catalonia
-
Barcelona、Catalonia、スペイン、119-129
- Hospital Universitari Vall D'Hebron
-
-
-
-
-
Lyon、フランス
- Centre Leon Berard
-
Pessac、フランス、33604
- Hospital Haut Leveque, CHU Bordeaux
-
Villejuif、フランス、94805
- Gustave Roussy Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria
- Age ≥16 (10 years at selected sites) and <=75 years
- Diagnosis of advanced synovial sarcoma (Cohort 1, Cohort 2 and Cohort 3) or myxoid liposarcoma / myxoid round cell liposarcoma (Cohort 1 only) confirmed by cytogenetics.
- Previously received either an anthracycline or ifosfamide containing regimen.
- Measurable disease according to RECIST v1.1 prior to lymphodepletion
- HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 positive
- Tumor shows MAGE-A4 expression confirmed by central laboratory. North America Only (United States and Canada): Tumor (either an archival specimen or a fresh biopsy) shows MAGE-A4 expression of ≥2+ staining in ≥30% of the cells by immunohistochemistry.
- ECOG Performance Status of 0 or1. For subjects aged ≥10 to ≥16 years old:
Lansky Score ≥60%.
• Left ventricular ejection fraction (LVEF) ≥50%.
Note: other protocol defined Inclusion criteria may apply
Key Exclusion Criteria:
- HLA-A*02:05 in either allele
- Received or plans to receive the following therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy: Cytotoxic chemotherapy, Tyrosine kinase inhibitor (TKI) (e.g. pazopanib), Immune therapy (including monoclonal antibody therapy, checkpoint inhibitors,), Anti-cancer Vaccine, Gene therapy using an integrating vector (subjects who have received a gene therapy using a lentiviral vector may be eligible for the study), Corticosteroids or any other immunosuppressive therapy, Investigational treatment or interventional clinical trial, Allogeneic hematopoietic stem cell transplant, Radiotherapy to the target lesions, Major surgery
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
- History of autoimmune or immune mediated disease
- Symptomatic CNS metastases including leptomeningeal disease.
- Other prior malignancy that is not considered by the Investigator to be in complete remission
- Clinically significant cardiovascular disease
- Uncontrolled intercurrent illness
- Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus
- Pregnant or breastfeeding
Note: other protocol defined Exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:自家遺伝子改変 afamitresgene autoleucel (以前の ADP-A2M4) SPEAR™ T 細胞
|
Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response Rate (ORR) (Cohort 1)
時間枠:From T-cell infusion until disease progression/recurrence as of data cut off (up to 2 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
Percentage of participants with confirmed tumor response (complete [CR] or partial [PR] response) to treatment as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Independent Radiologist review (Cohort 1) |
From T-cell infusion until disease progression/recurrence as of data cut off (up to 2 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse Events (AE) Including Serious Adverse Events (SAE), SAE, and Adverse Events of Special Interest (AESI) (Cohort 1)
時間枠:AEs, SAEs, and AESIs were collected at each visit from the start of lymphodepletion of the first subject until the last subject discontinued the interventional phase in cohort 1 as of the safety cut off (up to 3.2 years).
|
An AE was defined as any untoward medical occurrence in a subject or clinical study participant temporally associated with the use of the study intervention, whether or not considered related to the study intervention. Therefore, an AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants with AEs (including SAE), SAE and AESI including cytokine release syndrome, neurotoxicity, ICANS, prolonged cytopenia are presented. |
AEs, SAEs, and AESIs were collected at each visit from the start of lymphodepletion of the first subject until the last subject discontinued the interventional phase in cohort 1 as of the safety cut off (up to 3.2 years).
|
|
The Number of Participants With Replication Competent Lentivirus (RCL)
時間枠:From T-cell infusion to months 3, 6, and 12 post-infusion, then annually post-infusion (up to 2.8 years as of the data cut off).
|
The presence of RCL was assessed by qPCR targeting a segment of the vesicular stomatitis virus glycoprotein (VSV G) coding sequence. |
From T-cell infusion to months 3, 6, and 12 post-infusion, then annually post-infusion (up to 2.8 years as of the data cut off).
|
|
Insertional Oncogenesis (IO)
時間枠:From 10 months post T-cell infusion up to 20 months post T-cell infusion (as of the data cut off)
|
Deoxyribonucleic acid (DNA) from participants peripheral blood mononuclear cell (PBMC) samples was subjected to lentiviral vector integration site analysis by next-generation sequencing, thus evaluating both the clonality status of the transduced cell population and the genomic localization of individual integration sites. The count of participants with integration sites representing more than 5% of all unique sites is presented. |
From 10 months post T-cell infusion up to 20 months post T-cell infusion (as of the data cut off)
|
|
Best Overall Response (BOR) (Cohort 1)
時間枠:From T-cell infusion until disease progression/recurrence as of data cut off (up to 2.6 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
BOR is the best response recorded from the start of T-cell infusion until disease progression/recurrence as assessed by Independent Radiologist review. Response categories are confirmed CR, confirmed PR, stable disease and confirmed progressive disease (PD). Best overall response is a stable disease, if CR or PR are unconfirmed. |
From T-cell infusion until disease progression/recurrence as of data cut off (up to 2.6 years). Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
|
Time to Response (TTR) (Cohort 1)
時間枠:From T-cell infusion until first documented confirmed CR or confirmed PR. Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
TTR was defined as the interval (weeks) from the date of T-cell infusion to the earliest date of the first documented confirmed CR or confirmed PR as assessed by Independent Radiologist review. TTR (in weeks) = [date of initial confirmed CR or PR - date of T-cell infusion + 1]/7. |
From T-cell infusion until first documented confirmed CR or confirmed PR. Response was assessed at Week 4, Week 8, Week 12, Week 16, and Week 24, and every 2 months +/- 28 days until confirmed disease progression.
|
|
Duration of Response (DoR) (Cohort 1)
時間枠:From initial confirmed response (CR or PR) until PD (or censored date) as of data cut off.
|
DoR (in months) is defined as ((date of PD (or censoring) - date of initial confirmed CR/PR + 1)/365.25)*12 as assessed by Independent Radiologist review. Outcome Measure not yet reached as participants are ongoing in study |
From initial confirmed response (CR or PR) until PD (or censored date) as of data cut off.
|
|
Progression Free Survival (PFS) (Cohort 1)
時間枠:From T-cell infusion until first documented PD or death due to any cause (or censored date), whichever occurs first, as of data cut off (up to 2.6 years). Response was assessed at Week 4, 8,12,16, 24, and every 2 months until confirmed PD
|
PFS is defined as the time from T-cell infusion to the date of the first documentation of PD or death due to any cause, whichever occurs first, as assessed by Independent Radiologist review. PFS (in weeks) was calculated as (date of PD/death [or censored date] - first T-cell infusion date + 1)/7. |
From T-cell infusion until first documented PD or death due to any cause (or censored date), whichever occurs first, as of data cut off (up to 2.6 years). Response was assessed at Week 4, 8,12,16, 24, and every 2 months until confirmed PD
|
|
Overall Survival (OS) (Cohort 1)
時間枠:From T-cell infusion to death due to any reason (or censored date) as of data cut off (up to 2.6 years).
|
OS is defined as the time from the date of T-cell infusion to the date of death (due to any reason) or censored date. OS in months was calculated as ((death date - first T-cell infusion date + 1)/365.25)*12. Outcome Measure not yet reached as participants are ongoing in study |
From T-cell infusion to death due to any reason (or censored date) as of data cut off (up to 2.6 years).
|
|
Peak Persistence (Cohort 1)
時間枠:From T-cell infusion to 3.2 years (as of data cut off).
|
Peak persistence of afamitresgene autoleucel cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC). |
From T-cell infusion to 3.2 years (as of data cut off).
|
|
Time Taken to Achieve Peak Expansion of Genetically Engineered T-cells in PBMCs
時間枠:2.5 years
|
Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by flow cytometry |
2.5 years
|
|
Quantitation of Genetically Engineered T-cells in PBMCs
時間枠:2.5 years
|
Quantitation of genetically engineered T-cells in PBMCs by flow cytometry |
2.5 years
|
|
Time Taken to Achieve Peak Expansion of Genetically Engineered T-cells in PBMCs
時間枠:2.5 years
|
Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by qPCR |
2.5 years
|
|
In Vitro Diagnostic (IVD) Assay for Screening
時間枠:2.5 years
|
Development and validation of the MAGE-A4 antigen expression companion diagnostic assay |
2.5 years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Dejka Araujo, MD、MD Anderson Cancer Center; Houston TX 77030
出版物と役立つリンク
一般刊行物
- Sanderson JP, Crowley DJ, Wiedermann GE, Quinn LL, Crossland KL, Tunbridge HM, Cornforth TV, Barnes CS, Ahmed T, Howe K, Saini M, Abbott RJ, Anderson VE, Tavano B, Maroto M, Gerry AB. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology. 2019 Nov 24;9(1):1682381. doi: 10.1080/2162402X.2019.1682381. eCollection 2020.
- D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13;403(10435):1460-1471. doi: 10.1016/S0140-6736(24)00319-2. Epub 2024 Mar 27.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。